Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 33, Issue 2, Pages 129-142
Publisher
Elsevier BV
Online
2021-12-01
DOI
10.1016/j.annonc.2021.11.005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
- (2021) Paul Baas et al. LANCET
- Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma
- (2021) Kathrin Oehl et al. CLINICAL CANCER RESEARCH
- Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: A systematic review and meta-analysis of randomized trials
- (2021) Chia Ching Lee et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743
- (2021) S. Peters et al. ANNALS OF ONCOLOGY
- A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.
- (2021) Dean Anthony Fennell et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2021) Carmine Pinto et al. LANCET ONCOLOGY
- Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
- (2021) Cornedine J de Gooijer et al. Lancet Respiratory Medicine
- Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
- (2021) Dean A Fennell et al. Lancet Respiratory Medicine
- Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆
- (2021) J. Arends et al. ESMO Open
- Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
- (2021) Dean A Fennell et al. LANCET ONCOLOGY
- Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population‐based study
- (2020) Eunice Sirri et al. INTERNATIONAL JOURNAL OF CANCER
- Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use
- (2020) Naomi Alpert et al. Translational Lung Cancer Research
- ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
- (2020) Isabelle Opitz et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition
- (2020) Bahil Ghanim et al. Scientific Reports
- Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901
- (2020) Arkadiusz Z. Dudek et al. Clinical Lung Cancer
- A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
- (2020) S. Popat et al. ANNALS OF ONCOLOGY
- LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743
- (2020) A. Scherpereel et al. ANNALS OF ONCOLOGY
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial
- (2019) Fraser Brims et al. THORAX
- Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
- (2019) Maria J Disselhorst et al. Lancet Respiratory Medicine
- Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma
- (2019) Raffit Hassan et al. JAMA Oncology
- Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial
- (2019) Neil Bayman et al. JOURNAL OF CLINICAL ONCOLOGY
- Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life
- (2019) Emily Jeffery et al. EUROPEAN JOURNAL OF CLINICAL NUTRITION
- Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study
- (2019) Dean A. Fennell et al. JOURNAL OF CLINICAL ONCOLOGY
- Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
- (2019) Raffit Hassan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
- (2019) Giorgio V Scagliotti et al. Lancet Respiratory Medicine
- High Time for Complete Ban on Asbestos Use in Developing Countries
- (2019) Tianhui Chen et al. JAMA Oncology
- Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial
- (2019) Guillaume Eberst et al. CLINICAL CANCER RESEARCH
- Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT)
- (2019) Morihito Okada et al. CLINICAL CANCER RESEARCH
- MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma
- (2019) David B. Chapel et al. MODERN PATHOLOGY
- EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.
- (2019) Andrew G. Nicholson et al. Journal of Thoracic Oncology
- Malignant mesothelioma in situ: morphologic features and clinical outcome
- (2019) Andrew Churg et al. MODERN PATHOLOGY
- Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel
- (2019) Alberto M. Marchevsky et al. MODERN PATHOLOGY
- Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy
- (2019) Christina Schröder et al. Frontiers in Oncology
- Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting
- (2019) Yu Zhi Zhang et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study
- (2018) Sahar A. Saddoughi et al. ANNALS OF THORACIC SURGERY
- Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group
- (2018) Aliya Noor Husain et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma
- (2018) Josine Quispel-Janssen et al. Journal of Thoracic Oncology
- Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
- (2018) Samuel G. Armato et al. Journal of Thoracic Oncology
- Novel therapies for malignant pleural mesothelioma
- (2018) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study
- (2018) Lauren E Rosen et al. MODERN PATHOLOGY
- A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma
- (2018) Fausto Petrelli et al. RESPIRATORY MEDICINE
- Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
- (2018) Luana Calabrò et al. Lancet Respiratory Medicine
- Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial
- (2018) Sanjeevan Muruganandan et al. Lancet Respiratory Medicine
- Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM).
- (2018) Arpita Desai et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-life treatment practice for malignant pleural mesothelioma in Belgium
- (2018) Michael Rosskamp et al. LUNG CANCER
- A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma
- (2018) Stephanie R. Rice et al. PHOTOCHEMISTRY AND PHOTOBIOLOGY
- Integrative Molecular Characterization of Malignant Pleural Mesothelioma
- (2018) Julija Hmeljak et al. Cancer Discovery
- Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma
- (2017) Ellen D. Yorke et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
- (2017) Evan W Alley et al. LANCET ONCOLOGY
- Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma
- (2016) Diana Y. Kircheva et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma
- (2016) Andreas Rimner et al. JOURNAL OF CLINICAL ONCOLOGY
- Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma
- (2016) Marc de Perrot et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
- Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma
- (2016) Andrea Billé et al. Journal of Thoracic Oncology
- The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
- (2016) David Rice et al. Journal of Thoracic Oncology
- The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma
- (2016) Valerie W. Rusch et al. Journal of Thoracic Oncology
- The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
- (2016) Anna K. Nowak et al. Journal of Thoracic Oncology
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
- (2016) Amelia O Clive et al. LANCET ONCOLOGY
- Meta-Analysis of Survival After Pleurectomy Decortication Versus Extrapleural Pneumonectomy in Mesothelioma
- (2015) Emanuela Taioli et al. ANNALS OF THORACIC SURGERY
- Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors
- (2015) Emilio Minatel et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Beam-specific planning target volumes incorporating 4D CT for pencil beam scanning proton therapy of thoracic tumors
- (2015) Liyong Lin et al. Journal of Applied Clinical Medical Physics
- Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial
- (2015) Nicholas MacLeod et al. Journal of Thoracic Oncology
- Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial
- (2015) Rolf A Stahel et al. LANCET ONCOLOGY
- Extrapleural Pneumonectomy in the Treatment of Epithelioid Malignant Pleural Mesothelioma
- (2014) David J. Sugarbaker et al. ANNALS OF SURGERY
- A Propensity-Matched Comparison of Pleurodesis or Tunneled Pleural Catheter for Heart Failure Patients With Recurrent Pleural Effusion
- (2014) Richard K. Freeman et al. ANNALS OF THORACIC SURGERY
- Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial
- (2014) Robert C Rintoul et al. LANCET
- Radiotherapy for the treatment of pain in malignant pleural mesothelioma: A systematic review
- (2013) N. MacLeod et al. LUNG CANCER
- A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma
- (2013) Christopher Cao et al. LUNG CANCER
- Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung
- (2012) Emilio Minatel et al. Journal of Thoracic Oncology
- Biomarkers for Malignant Pleural Mesothelioma
- (2012) Laurent Greillier et al. Molecular Diagnosis & Therapy
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
- (2011) Tom Treasure et al. LANCET ONCOLOGY
- Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program
- (2010) Paul Taylor et al. Journal of Thoracic Oncology
- What is the best way to diagnose and stage malignant pleural mesothelioma?
- (2010) I. Zahid et al. Interactive Cardiovascular and Thoracic Surgery
- Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma
- (2009) Claus Andrup Kristensen et al. RADIOTHERAPY AND ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started